Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730279 | 0.90 | NPC1 (0.53) | CNR1CNR2MAPTALDH1A1MEN1 | |
| SCHEMBL17713154 | 0.90 | CNR1 (0.49) | CNR1CNR2MAPTALDH1A1MEN1 | |
| SCHEMBL16730277 | 0.89 | NPC1 (0.57) | CNR1CNR2MAPTALDH1A1KMT2A | |
| SCHEMBL18028126 | 0.87 | MAPT (0.49) | CNR1CNR2MAPTALDH1A1MEN1 | |
| SCHEMBL7091874 | 0.80 | CNR1 (0.78) | CNR1CNR2MAPTALDH1A1MEN1 | |
| SCHEMBL18058762 | 0.78 | HDAC8 (0.41) | MAPTALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL21890845 | 0.78 | RPS6KA3 (0.40) | MAPTALDH1A1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL18058760 | 0.78 | PTGS2 (0.41) | MAPTMEN1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL16730425 | 0.78 | MAPT (0.44) | CNR1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL18410384 | 0.77 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099963-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | UNICHEM LAB LTD (IN) | 2018-04-12 | — | — | US | disclosed |
| US-9932336-B2 | Process for the preparation of apixaban and intermediates thereof | Jubilant Generics Limited (IN) | 2018-04-03 | — | — | US | disclosed |
| US-9908881-B2 | Process for the preparation of apixaban and intermediates thereof | UNICHEM LABORATORIES LIMITED (IN) | 2018-03-06 | — | — | US | disclosed |
| US-20170362232-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | UNICHEM LAB LTD (IN) | 2017-12-21 | — | — | US | disclosed |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (IN) | 2017-11-02 | — | — | US | disclosed |
| US-20170015663-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | UNICHEM LABORATORIES LIMITED (IN) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099963-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | HAX1, CYP4X1, HTRA1 | CNR1 947/4885CNR2 842/4885MAPT 4264/4885 |
| US-20170362232-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | HAX1, CYP4X1, HTRA1 | CNR1 947/4885CNR2 842/4885MAPT 4264/4885 |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, CYP4X1 | CNR1 820/4885CNR2 718/4885MAPT 4806/4885 |
| US-20170015663-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | HAX1, CYP4X1, HTRA1 | CNR1 947/4885CNR2 842/4885MAPT 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.